Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly already has market share in the breast cancer space with the approved drug Verzenio (abemaciclib), and is advancing investigational drugs like the oral selective estrogen receptor degrader ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention ...

Abemaciclib (Verzenio / Verzenios / Yulareb / Zenlistik ... extra-heaptic bile duct cancer and high-risk metastatic hormone-sensitive prostate cancer. Eli Lilly and Co (Lilly) is a healthcare company ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

Eli Lilly has backed away from plans to file ... failure therapy Jardiance (empagliflozin), and breast cancer therapy Verzenio (abemaciclib). Join the conversation, on Tuesday 28th January ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...